NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0

Trial Profile

NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NewEra
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2010 Planned end date changed from 1 Nov 2016 to 1 Nov 2019 as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top